1,5-Dihydroxyisoquinoline can inhibit PARP1 and NF-κB/AP-1 [266,267] and FK866 can suppress NAMPT, thereby reducing mucosal immunity in intestinal isolated lamina propria monocytes (LPMNC) and DSS mice in IBD patients and cytokine release [18]. Here, PARP1 is linked to inflammatory bowel disease.